While Agios Pharmaceuticals Inc has overperformed by 0.77%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AGIO rose by 38.68%, with highs and lows ranging from $35.50 to $19.80, whereas the simple moving average jumped by 17.92% in the last 200 days.
On February 08, 2024, Cantor Fitzgerald started tracking Agios Pharmaceuticals Inc (NASDAQ: AGIO) recommending Overweight. A report published by Piper Sandler on February 03, 2023, Initiated its previous ‘Overweight’ rating for AGIO. Goldman also Upgraded AGIO shares as ‘Neutral’, setting a target price of $32 on the company’s shares in a report dated November 17, 2022. BofA Securities initiated its ‘Buy’ rating for AGIO, as published in its report on December 03, 2021. Goldman’s report from July 30, 2021 suggests a price prediction of $39 for AGIO shares, giving the stock a ‘Sell’ rating. Raymond James also rated the stock as ‘Mkt Perform’.
Analysis of Agios Pharmaceuticals Inc (AGIO)
Further, the quarter-over-quarter increase in sales is 64.80%, showing a positive trend in the upcoming months.
To gain a thorough understanding of Agios Pharmaceuticals Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -36.83% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 11.99, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and AGIO is recording an average volume of 809.57K. On a monthly basis, the volatility of the stock is set at 3.63%, whereas on a weekly basis, it is put at 4.63%, with a gain of 5.16% over the past seven days. Furthermore, long-term investors anticipate a median target price of $40.67, showing growth from the present price of $29.94, which can serve as yet another indication of whether AGIO is worth investing in or should be passed over.
How Do You Analyze Agios Pharmaceuticals Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 2.58%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 106.21% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
AGIO shares are owned by institutional investors to the tune of 106.21% at present.
